Clearstate white papersMedTech Industry White Papers Clearstate’s white papers provide practical business information on a wide range of topics, from latest industry trends to regional analysis. Each report contains a broad overview of medtech sectors including in vitro diagnostics and surgical devices, followed by a detailed analysis of underlying issues and forecasts to help you operate more effectively.
Going global: opportunities for Chinese IVD companies Opportunistic growth opportunities from covid-19 have helped… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Middle East & Africa
A new era of IVD demand in emerging markets While emerging markets have grown and exceeded their… Uncategorised | Americas | Asia
Next-generation sequencing (NGS) in cancer biomarker testing Over the past two years, the global in-vitro diagnostics… Uncategorised | Global
Next-generation sequencing (NGS) in cancer biomarker testing: trends in European labs Next-generation sequencing (NGS) in cancer biomarker… Europe
The Future of TAVR in Asia Understand the future of cardiac surgery in Asia with… Uncategorised | Asia
The future of molecular diagnostics following the covid-19 crisis in Asia-Pacific Molecular-based testing has become fundamental to many… Uncategorised | Asia
Keeping ahead of infectious diseases in Asia-Pacific with increased testing Our new briefing paper looks at the testing trends in… Covid-19 testing | In-vitro diagnostics | Infectious Diseases Testing Monitor | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Asia | IVD Gateway | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Point-of-care testing (POCT)
The Future of Point-of-care Testing in Latin America EIU Healthcare latest report explores how Latin American… Uncategorised | Americas
Sign up to our free newsletterThe latest trends and insights into the IVD and Surgical sectors, from our specialists and analysts, delivered directly to your inbox. Sign up to Clearstate’s newsletter today. Sign up now